Sacubitril and Valsartan (Entresto®)

Sacubitril and valsartan (Entresto®) is available under the Community Drug Schemes since December 2017. A managed access approach is undertaken with clinical criteria that must be satisfied in order for a patient to be recommended for reimbursement of sacubitril and valsartan (Entresto®).

A clinician must submit an online application for individual reimbursement approval for each patient. All clinicians (GPs and hospital prescribers), once user-registered with the HSE-Primary Care Reimbursement Service (PCRS), can apply for reimbursement of sacubitril and valsartan (Entresto®). Due to the information that is required to be submitted, the clinician responsible for the initiation of treatment should complete the online application.

A copy of sacubitril and valsartan (Entresto®) clinical and reimbursement information and previous correspondence issued to prescribers can be found in the related files section below.

In September 2023, 6,513 patients were accessing sacubitril/valsartan under this protocol. Between December 2017 and September 2023, expenditure on sacubitril/valsartan on the Community Drug Schemes was €34.3 million. Click here for more information.